Sign inJoin waitlistJoin the waitlist

Sarina Piha-Paul

Fellowship Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center Fellowship
Present
Phase I Fellowship · University of Texas M D Anderson Cancer Center
Present
EMP Cancer Research Training and Education Coordination Liaison · University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2006–2009
Internal Medicine
Baylor College of Medicine
2002–2005
Louisiana State University School of Medicine in New Orleans
1998–2002

Research

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Journal of Clinical Investigation · 2017 · 3,119 citations
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology · 2020 · 2,397 citations
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort,…
The Lancet Oncology · 2020 · 2,115 citations

David Hong
167 papers
Aung Naing
153 papers
Siqing Fu
148 papers
Apostolia Tsimberidou
135 papers
Funda Meric-Bernstam
124 papers
FJ
Filip Janku
114 papers
Vivek Subbiah
99 papers
DK
Daniel Karp
77 papers
Razelle Kurzrock
75 papers
GF
Gerald Falchook
69 papers
JW
Jennifer Wheler
66 papers
RZ
Ralph Zinner
42 papers

Clinical trials

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2022–2027
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1, Phase 2
TransThera Sciences (Nanjing), Inc.
2021–2024
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Principal investigator · Terminated · Phase 1
ABM Therapeutics Corporation
2020–2024
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Principal investigator · Completed · Phase 1
TransThera Sciences (Nanjing), Inc.
2019–2024